EMA published the assessment report for Nuvaxovid supporting its extension of indication to include adolescents aged 12 to 17
01/08/2022
01/08/2022
| COVID-19 vaccines | Country |
|---|---|
| Abdala of Center for Genetic Engineering and Biotechnology (CIGB) | Click to see the list |
| Ad26.COV2.S of Janssen (Johnson & Johnson) | Click to see the list |
| AstraZeneca of SK BIO | Click to see the list |
| Aurora-CoV of Vector State Research Center of Virology and Biotechnology | Russia |
| BBIBP-CorV of Beijing Institute of Biological Products; China National Pharmaceutical Group (Sinopharm) | Click to see the list |
| Comirnaty (BNT162b2) of Pfizer-BioNTech | Click to see the list |
| Convidecia of CanSino Biologics | Click to see the list |
| Corbevax of Biological E Limited | India |
| CoronaVac of Sinovac Research and Development | Click to see the list |
| Covaxin (BBV152) of Bharat Biotech | Click to see the list |
| Covifenz of Medicago | Canada |
| COVIran Barekat of Shifa Pharmed Industrial Group | Iran |
| Covishield of Serum Institute of India | Click to see the list |
| COVOVAX (Novavax formulation) of Serum Institute of India | Click to see the list |
| EpiVacCorona of Vector State Research Center of Virology and Biotechnology | Click to see the list |
| FAKHRAVAC (MIVAC) of Organization of Defensive Innovation and Research | Iran |
| Gam-COVID-Vac of Gamaleya | Russia |
| GEMCOVAC-19 of Gennova Biopharmaceuticals | India |
| Inactivated vaccine of Chinese Academy of Medical Sciences | China |
| KCONVAC of Minhai Biotechnology Co | China; Indonesia |
| KoviVac of Chumakov Center | Russia; Belarus; Cambodia |
| MVC-COV1901 of Medigen | Paraguay; Somaliland; Taiwan |
| Noora of Baqiyatallah University of Medical Sciences | Iran |
| Nuvaxovid of Novavax | Click to see the list |
| QazVac of Research Institute for Biological Safety Problems (RIBSP) | Kazakhstan; Kyrgyzstan |
| Razi Cov Pars of Razi Vaccine and Serum Research Institute | Iran |
| Recombinant SARS-CoV-2 Vaccine (CHO Cell) of National Vaccine and Serum Institute | United Arab Emirates |
| SKYCovione of SK Bioscience | Corea del sur |
| Soberana 02 of Finlay Institute of Vaccines | Click to see the list |
| Soberana Plus of Finlay Institute of Vaccines | Click to see the list |
| Spikevax (mRNA-1273) of Moderna | Click to see the list |
| Spikogen of Vaxine/CinnaGen Co | Iran |
| Sputnik Light of Gamaleya/ | Click to see the list |
| Sputnik V of Gamaleya | Click to see the list |
| TAK-919 (Moderna formulation) of Takeda | Japan |
| Turkovac of Health Institutes of Turkey | Turkey |
| Vaxzevria of AstraZeneca/Oxford | Click to see the list |
| VLA2001 of Valneva | Bahrain |
| WIBP-CorV of Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm) | Click to see the list |
| Zifivax of Anhui Zhifei Longcom | Click to see the list |
| ZyCoV-D of Zydus Cadila | India |
| Adopted Name | Name | EUL holder and NRA responsable | Authorized sites (Finished product - countries) |
|---|---|---|---|
| Pfizer-BioNTech COVID-19 vaccine 2BNT162b2; Tozinameran; Comirnaty |
COMIRNATY® COVID-19 mRNA Vaccine (nucleoside modified) | Holder: BioNTech Manufacturing GmbH, Alemania NRA responsable: European Medicines Agency (EMA) Effective date: 31/12/2020 Reference Link:http://bit.ly/3NwlDFa |
Authorized site: EE.UU. NRA Food and Drug Administration (FDA), USA Efective date: 16/7/2021 Reference Link: https://bit.ly/3wPb0Hr |
| EU Nodes-AstraZeneca/ Oxford COVID-19 vaccine; Vaxzevria in Europe (formerly AZD1222 and ChAdOx1)* | Vaxzevria COVID-19 Vaccine (ChAdOx1-S [recombinant]) |
Holder: AstraZeneca/SK Bioscience Co. Ltd, Republica de Corea NRA responsable: Ministry of Food and Drug Safety Effective date: 15/2/2021 Reference Link: http://bit.ly/3NxXKNg |
|
| EU Nodes-AstraZeneca/ Oxford COVID-19 vaccine; Vaxzevria in Europe (formerly AZD1222 and ChAdOx1)* | Vaxzevria COVID-19 Vaccine (ChAdOx1-S [recombinant]) |
Holder: AstraZeneca AB NRA responsable: European Medicines Agency EMA Effective date: 15/4/2021 Reference Link: https://bit.ly/3KDGlkr |
Authorized sites: (1) Italia, Japón RNA responsable: Ministry of Health, Labour and Welfare, Japon Efective date (1): 09/7/2021 Reference Link site: https://bit.ly/3iQGepq Authorized sites: (2) EE.UU, Italia, Reino Unido, Alemania, Australia, Tailandia RNA responsable: Therapeutic Goods Administration, Australia Efective date (2): 09/7/2021 Reference Link site: https://bit.ly/3wOMhTL Authorized sites: (3) Italia, Reino Unido, Alemania, Australia, EE.UU RNA responsable: Health Canadá Efective date (3): 21/8/2021 Reference Link site: https://bit.ly/3Loo0Ic Authorized sites: (4) Argentina, México RNA responsable: COFEPRIS, México; ANMAT, Argentina Efective date (4): 23/12/2021 Reference Link site: https://bit.ly/3uCVCeB |
| Serum Institute of India COVID-19 vaccine; Covishield in India* |
COVISHIELD™ COVID-19 Vaccine (ChAdOx1-S [recombinant]) |
Holder: Serum Institute of India Pvt. Ltd. NRA responsable: Central Drugs Standard Control Organization Effective date: 15/4/2021 Reference Link: https://bit.ly/3KDGlkr |
|
| Janssen COVID-19 vaccine JNJ-78436735; Ad26.COV2-S (recombinant). | COVID-19 Vaccine (Ad26.COV2-S [recombinant]) | Holder: Janssen–Cilag International NV. NRA responsable: European Medicines Agency EMA Effective date: 12/3/2021 Reference Link: https://bit.ly/382QkkW |
|
| Moderna COVID-19 vaccine mRNA-1273* | Spikevax COVID-19 mRNA Vaccine (nucleoside modified) |
Holder: Moderna Biotech NRA responsable: European Medicines Agency EMA Effective date: 30/4/2021 Reference Link: https://bit.ly/3DsvHum |
Authorized sites: República de Korea RNA responsable: Ministry of Food and Drug Safety (MFDS), Republic of Korea Efective date: 23/12/2021 Reference Link: https://bit.ly/3wORR8F |
| Moderna COVID-19 vaccine mRNA-1273* | Spikevax COVID-19 mRNA Vaccine (nucleoside modified) |
Holder: Moderna TX,Inc. RNA responsable: FDA, USA Effective date: 6/8/2021 Reference Link: https://bit.ly/3wR7BrW |
|
| Sinopharm/ BIBP COVID-19 vaccine Inactivated SARS-CoV-2-vaccine (Vero cell); BBIBP-CorV | Inactivated COVID-19 Vaccine (Vero Cell) | Titular: Beijing Institute of Biological Products Co., Ltd. (BIBP) ARN responsable: National Medicinal Products Association Effective date: 7/5/2021 Reference Link: https://bit.ly/3K0A56k |
|
| Sinovac COVID-19 vaccine CoronaVac; adsorbed COVID-19 vaccine | CoronaVac COVID-19 Vaccine (Vero Cell), Inactivated |
Titular: Sinovac Life Sciences Co., Ltd. China ARN responsable: National Medicinal Products Association Effective date: 1/6/2021 Reference Link: https://bit.ly/3NysEFh |
|
| Bharat Biotech COVID-19 vaccine; Covaxin; BBV152 Suspension of supply |
COVAXIN® Covid-19 vaccine (Whole Virion Inactivated Corona Virus vaccine) |
Holder: Bharat Biotech International Limited RNA responsable: Central Drugs Standard Control Organization Effective date: 3/11/2021 Reference Link: https://bit.ly/36EjcQg |
|
| Novavax vaccine COVID-19; NVX-CoV2373 | COVOVAX™ COVID-19 vaccine (SARS-CoV-2 rS Protein Nanoparticle [Recombinant]) |
Holder: Serum Institute of India Pvt. Ltd RNA responsable: Central Drugs Standard Control Organization Effective date: 17/12/2021 Reference Link: https://bit.ly/3uAxHwq |
|
| Novavax vaccine COVID-19; NVX-CoV2373 | NUVAXOVID™ COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]) | Holder: Novavax CZ a.s RNA responsable: European Medicines Agency EMA Effective date: 20/12/2021 Reference Link: https://bit.ly/3qPVFmp |
|
| COVID-19 Vaccine, (Ad5.CoV2-S [Recombinant]) |
Convidecia COVID-19 Vaccine, (Ad5.CoV2-S [Recombinant]) | Holder: CanSino Biologics Inc. RNA responsable: National Medical Products Administration (NMPA) Effective date: 19 May 2022 Reference Link: https://extranet.who.int/pqweb/vaccines/convidecia |
*Vaccines that have different authorizations, but with the same developer.
It is suggested to use the filters to select the variables with more information
| Anhui Zhifei Longcom COVID-19 vaccine | AstraZeneca/ Oxford; SK BIO; Serum Institute of India COVID-19 vaccine | Bharat Biotech COVID-19 vaccine (suspended supply) [8] | CanSino COVID-19 vaccine | CIGB COVID-19 vaccine | Finlay Institute COVID-19 vaccine | Gamaleya COVID-19 vaccine | Janssen COVID-19 vaccine | Moderna COVID-19 vaccine | Novavax COVID-19 vaccine | Pfizer-BioNTech COVID-19 vaccine | Sinopharm/BIBP COVID-19 vaccine | Sinopharm/WIBP COVID-19 vaccine | Sinovac COVID-19 vaccine | Vector Institute COVID-19 vaccine | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alpha B.1.1.7 | 88.3 (66.8 to 97.0) [1] | 70% (44% to 84%) [2] | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | 86% (71% to 83%) [7] | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported |
| Beta B.1.351 | Has not been measured or reported | 10% (0% to 55%) [3] | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | 52% (30% to 67%) [6] | Has not been measured or reported | 43% (0% to 70%) [8] | 100% (54% to 100%) [9] | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported |
| Gamma P.1 | Has not been measured or reported | 63.6% (0.00% to 87.00%) [4] | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported |
| Delta B.1.617.2 | 76.1 (70.0 to 81.2) [1] | Has not been measured or reported | 65% (33% to 83%) [5] | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported |
| Omicron B.1.1.529 | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported | Has not been measured or reported |
It is suggested to use the filters to select the variables with more information
It is suggested to use the filters to select the variables with more information
It is suggested to use the filters to select the variables with more information
| Myocarditis/pericarditis | Guillain-Barré Syndrome (GBS) | Thrombosis with thrombocytopenia syndrome (TTS) | Capillary leak syndrome (CLS) | Cerebral venous sinus thrombosis (CVST) without thrombocytopenia | Menstrual disorders | Multisystem inflammatory syndrome (MIS) | Small vessel vasculitis with cutaneous manifestations | Autoimmune Hepatitis (AIH) | |
|---|---|---|---|---|---|---|---|---|---|
| AstraZeneca/Oxford; SK BIO; Serum Institute of India COVID-19 vaccine | NA | GBS has been reported very rarely (i.e. less than 1 in 10.000 vaccinees) following vaccination with Vaxzevria/Covishield. A causal relationship has neither confirmed, nor ruled out [2]. The benefits of the vaccine outweigh the risks of GBS [2]; [3]. | Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) were reported 3-21 days following vaccination with Vaxzevria/Covishield, mainly after the first dose. The benefits of vaccination outweigh the risks, especially in older age groups [2]; [4]. Vaxzevria is contraindicated in persons who have experienced TTS with previous doses of the vaccine [2]. | Very rare cases of capillary leak syndrome (CLS) were reported in the first days after vaccination with Vaxzevria, with fatal outcomes in some people with prior experience of CLS. EMA recommends that persons with a known history of CLS should not be vaccinated with Vaxzevria [5]. | Events of cerebrovascular venous and sinus thrombosis (CVST) without thrombocytopenia have been observed very rarely following vaccination with Vaxzevria, mostly within the first four weeks following vaccination. This information should be considered for individuals at increased risk for CVST [3]. | NA | NA | NA | NA |
| Bharat Biotech COVID-19 vaccine (suspended supply) | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| CanSino COVID-19 vaccine | NA | NA | Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) were reported globally (0.081 cases per 100.000 vaccinees as of December 2021) around 3-30 days following vaccination with CanSino [1]. | NA | NA | NA | NA | NA | NA |
| Janssen COVID-19 vaccine | NA | GBS has been reported very rarely following vaccination with Janssen COVID-19 vaccine. As of April 2022, 535 cases were reported globally (1.5 cases per million vaccinees) [6] The benefits of the vaccine outweigh the risks of GBS [6]. | Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) were reported following the first dose of Janssen COVID-19 vaccine. As of April 2022, 109 cases were reported globally (2 cases per million vaccinees) [6]. The benefits of vaccination outweigh the risks, especially in older age groups [4]. Janssen COVID-19 vaccine is contraindicated in persons who have experienced TTS with previous doses of the vaccine [4]; [6]. | Very rare cases of capillary leak syndrome (CLS) were reported in the first days after vaccination with Janssen COVID-19 vaccine, with fatal outcomes in some people with prior experience of CLS. EMA recommends that persons with a known history of CLS should not be vaccinated with Janssen COVID-19 vaccine [7]. | Venous thromboembolism (VTE) has been observed rarely following vaccination with Janssen COVID-19 vaccine. This should be considered for individuals at increased risk for VTE [8]. | NA | NA | PRAC/EMA recommends that small vessel vasculitis with cutaneous manifestations should be added to the product information of the Janssen COVID-19 vaccine as a possible side effect with unknown frequency [9]. | NA |
| Moderna COVID-19 vaccine | Myocarditis is a very rare adverse event (up to 1 in 10.000 vaccinated people) reported after receipt a mRNA COVID-19 vaccine. Available data suggest that the course of myocarditis/pericarditis following vaccination is generally mild and responds to treatment. The observed risk is highest in young males (aged 18-24 years) and within a few days after the second dose of Moderna COVID-19 vaccine [10]; [11]. The benefits of Spikevax continue to outweigh its risks in all age groups [10]. | NA | NA | In persons with history of this extremely rare condition, there is a potential occurrence of CLS flare-up following vaccination with Moderna COVID-19 vaccine [9]. | NA | The currently available evidence does not support a causal relationship between Moderna COVID-19 vaccine and amenorrhea. As of June 2022, PRAC/EMA is still assessing reported cases about heavy menstrual bleeding [12]. | NA | NA | According to PRAC/EMA, the available evidence does not support a causal link between Moderna COVID-19 vaccine and very rare cases of autoimmune hepatitis (AIH) [13]. |
| Novavax COVID-19 vaccine | As for August 2022, based on a small number of reported cases, the PRAC/EMA has concluded that myocarditis and pericarditis can occur after vaccination with Novavax [13]. | NA | NA | NA | NA | NA | NA | NA | NA |
| Pfizer-BioNTech COVID-19 vaccine | Myocarditis is a very rare adverse event (up to 1 in 10.000 vaccinated people) reported after receipt a mRNA COVID-19 vaccine. Available data suggest that the course of myocarditis and pericarditis following vaccination is generally mild and responds to treatment. The observed risk is highest in young males (aged 12-29 years) and higher after the second dose of Comirnaty [11]; [14]. The benefits of Comirnaty continue to outweigh its risks in all age groups [14]. | NA | NA | NA | NA | The currently available evidence does not support a causal relationship between Comirnaty and amenorrhea. As of June 2022, PRAC/EMA is still assessing reported cases about heavy menstrual bleeding [12]. | According to PRAC/EMA, there is currently insufficient evidence of a possible link between Comirnaty and very rare cases of multisystem inflammatory syndrome (MIS) [15]. | NA | According to PRAC-EMA, the available evidence does not support a causal link between Comirnaty and very rare cases of autoimmune hepatitis (AIH) [13]. |
| Sinopharm/BIBP COVID-19 vaccine | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Sinovac COVID-19 vaccine | NA | NA | NA | NA | NA | NA | NA | NA | NA |
It is suggested to use the filters to select the variables with more information
Individuals 5 to 11 years old |
Individuals 12 to 17 years old |
Individuals 18 years old and older |
Pregnant and breastfeeding women |
Immunocompromised persons (moderate and severe) | Heterologous scheme |
Booster dose |
|||
|---|---|---|---|---|---|---|---|---|---|
| 5 to 11 years old | 12 to 17 years old | 18 years and older | |||||||
| Anhui Zhifei Longcom COVID-19 vaccine (Authorized) [1] | Not recommended yet | Not recommended yet | INVIMA/Colombia: Three doses (0.5 mL each) 4 and 8 weeks apart. | INVIMA/Colombia: contraindicated in pregnant women. | Not recommended yet | Not recommended yet | INVIMA/Colombia: primary series of three doses (0.5 mL each) 4 and 8 weeks apart. | There is no available data on interchangeability. | There is no available data on booster doses beyond the third dose. |
| AstraZeneca/Oxford; AstraZeneca/SK BIO; Serum Institute of India COVID-19 vaccine (EUL/WHO authorization) [2] | Not recommended yet | Not recommended yet | SAGE/WHO: Two doses (0.5 mL each) 4 to 12 weeks apart. WHO recommends an interval of 8 to 12 weeks between doses. | SAGE/WHO: Two doses (0.5 mL each) 8 to 12 weeks apart. WHO recommends using the Vaxzevria/Covishield COVID-19 vaccine in pregnant women only if the benefits of vaccination outweigh the potential risks. | Not recommended yet | Not recommended yet | SAGE/WHO: Extended primary series with an additional (third) dose of 0.5 mL 1-3 months after the second dose, followed by a booster (fourth) dose provided 3-6 months after. | SAGE/WHO: Vaxzevria/Covishield combined with any other EUL COVID-19 vaccine is considered a complete primary series. | SAGE/WHO: A booster dose should be given 4-6 months after the primary series* using any other EUL vaccine (preferably an mRNA-based or Novavax vaccine). |
| Bharat Biotech COVID-19 vaccine (EUL/WHO authorization, suspended supply) [3] | Not recommended yet | Not recommended yet | SAGE/WHO: Two doses (0.5 mL each) 4 weeks apart. | SAGE/WHO: Two doses (0.5 mL each) 4 weeks apart. WHO recommends using the Bharat Biotech COVID-19 vaccine in pregnant women only if the benefits of vaccination outweigh the potential risks. | Not recommended yet | Not recommended yet | SAGE/WHO: Extended primary series with an additional (third) dose of 0.5 mL 1-3 months after the second dose, followed by a booster (fourth) dose provided 3-6 months after. | SAGE/WHO: Bharat Biotech COVID-19 vaccine combined with any other EUL COVID-19 vaccine is considered a complete primary series. | SAGE/WHO: A booster dose should be given 4-6 months after the primary series*. |
| CanSino COVID-19 vaccine (EUL/WHO authorization) [4] | Not recommended yet | Not recommended yet | SAGE/WHO: One dose of 0.5 mL. | SAGE/WHO: One dose of 0.5 mL. WHO recommends using the CanSino COVID-19 vaccine in pregnant women only if the benefits of vaccination outweigh the potential risks. | Not recommended yet | Not recommended yet | SAGE/WHO: Extended primary series with an additional (second) dose administered 1-3 months after the first dose. | SAGE/WHO: CanSino COVID-19 vaccine may be used as a booster dose following a primary series using any other EUL COVID-19 vaccine. | SAGE/WHO: A booster dose should be given 4-6 months after the primary series*. |
| CIGB (Abdala) COVID-19 vaccine (Authorized) [5] | CECMED/Cuba: 2 years of age and older. Three doses (0.5 mL) 2 weeks apart. | CECMED/Cuba: Three doses (0.5 mL) 2 weeks apart. | CECMED/Cuba: Three doses (50 µg, 0.5 mL) 2 weeks apart. | CECMED/Cuba: if the benefits of the vaccination outweigh the potential risks. | CECMED/Cuba: 2 years of age and older. Three doses (0.5 mL) 2 weeks apart. | CECMED/Cuba: Three doses (0.5 mL) 2 weeks apart. | CECMED/Cuba: Three doses (50 µg, 0.5 mL) 2 weeks apart. | There is no available data on interchangeability. | There is no available data on booster doses. |
| Finlay Institute of Vaccines COVID-19 vaccine (Authorized) [6] | CECMED/Cuba: SOBERANA 02 and SOBERANA 02 ST: 2 years of age and older. Two doses (0.5 mL) 4 weeks apart. SOBERANA PLUS and SOBERANA PLUS as a booster dose 4 weeks after. | CECMED/Cuba: SOBERANA 02 and SOBERANA 02 ST: Two doses (0.5 mL) 4 weeks apart. SOBERANA PLUS and SOBERANA PLUS as a booster dose 4 weeks after. | CECMED/Cuba: SOBERANA® 02 and SOBERANA® 02 ST: Two doses (0.5 mL each) 4 weeks apart. Soberana Plus and Soberana Plus ST: Single dose (0.5 mL) as a booster vaccine 4 weeks after a primary schedule with SOBERANA® 02 or SOBERANA® 02 ST. | CECMED/Cuba: if the benefits of the vaccination outweigh the potential risks. | CECMED/Cuba: SOBERANA 02 and SOBERANA 02 ST: 2 years of age and older. Two doses (0.5 mL) 4 weeks apart. SOBERANA PLUS and SOBERANA PLUS as a booster dose 4 weeks after. | CECMED/Cuba: SOBERANA 02 and SOBERANA 02 ST: Two doses (0.5 mL) 4 weeks apart. SOBERANA PLUS and SOBERANA PLUS as a booster dose 4 weeks after. | CECMED/Cuba: SOBERANA® 02 and SOBERANA® 02 ST: Two doses (0.5 mL each) 4 weeks apart. Soberana Plus and Soberana Plus ST: Single dose (0.5 mL) as a booster vaccine 4 weeks after a primary schedule with SOBERANA® 02 or SOBERANA® 02 ST. | There is no available data on interchangeability. | CECMED/Cuba: SOBERANA Plus and SOBERANA Plus ST may be used as a booster dose 4 weeks after a primary schedule with SOBERANA 02 or SOBERANA 02 ST. |
| Gamaleya COVID-19 vaccine (Authorized) [7],[8] | Not recommended yet | Not recommended yet | ANMAT/Argentina: Sputnik V: Two doses of different components (0,5ml each) 3 weeks apart. Sputnik Light: One dose (0.5 mL). | ISP/Chile: if the benefits of the vaccination outweigh the potential risks. | Not recommended yet | Not recommended yet | ANMAT/Argentina: primary schedule with Sputnik V, followed by an additional (third) dose 4 weeks after with Sputnik V (Component 1). | ANMAT/Argentina: a heterologous scheme using Sputnik V component 1 followed by a second dose of any authorized mRNA-based or viral vector vaccine may be used. | ANMAT/Argentina: A booster dose should be given at least 4 months after the primary scheme using an mRNA-based or viral vector vaccine. Component 1 of Sputnik V may be used as a booster dose. |
| Janssen COVID-19 vaccine (EUL/WHO authorization) [9] | Not recommended yet | Not recommended yet | SAGE/WHO: One or two doses (0.5 mL each). WHO recommends providing two doses with an interval of 2 to 6 months. | SAGE/WHO: One or two doses (0.5 mL each) 2-6 months apart. WHO recommends using the Janssen COVID-19 vaccine in pregnant women only if the benefits of vaccination outweigh the potential risks. | Not recommended yet | Not recommended yet | SAGE/WHO: Two doses (0.5 mL each) 1-3 months apart. | SAGE/WHO: the homologous two-dose schedule is the standard practice. However, a heterologous scheme using a second dose of an mRNA vaccine may be more immunogenic and effective. | SAGE/WHO: the need and timing of booster doses beyond the second dose are under assessment. |
| Moderna COVID-19 vaccine (EUL/WHO authorization) [10]-[12] | EMA: from 6 years of age. Two doses (50 µg, 0.5 mL each) 4 weeks apart. FDA: from 6 months of age. Two doses (25 µg, 0.25 mL each) 4 weeks apart. | SAGE/WHO: Two doses (100 µg, 0.5 ml each) 8 weeks apart. | SAGE/WHO: Two doses (100 µg, 0.5 ml each) 4 to 8 weeks apart. | SAGE/WHO: Two doses (100 µg, 0.5 mL each) 8 weeks apart. | EMA: from 6 years of age (50 µg dose). FDA: from 6 months of age (25 µg dose). Extended primary series with an additional (third) dose at least 1 month after the second dose. | SAGE/WHO: Extended primary series with an additional (third) 100 µg dose. 1-3 months after the second dose, and a booster (fourth) 50 µg dose provided 3-6 months after. | SAGE/WHO: Extended primary series with an additional (third) 100 µg dose 1-3 months after the second dose, and a booster (fourth) 50 µg dose provided 3-6 months after. | SAGE/WHO: Moderna COVID-19 vaccine combined with any other EUL COVID-19 vaccine is considered a complete primary series. | SAGE/WHO: A booster dose should be given 4-6 months after the primary series*. WHO recommends Moderna COVID-19 vaccine as a heterologous booster following a primary series with another platform. |
| Novavax/ Serum Institute of India COVID-19 vaccine (EUL/WHO authorization) [13] | Not recommended yet | Not recommended yet | SAGE/WHO: Two doses (0.5 mL each) 3-4 weeks apart. | SAGE/WHO: Two doses (0.5 mL each) 3 to 4 weeks apart. WHO recommends using the Novavax COVID-19 vaccine in pregnant women only if the benefits of vaccination outweigh the potential risks. | Not recommended yet | Not recommended yet | SAGE/WHO: Extended primary series with an additional (third) dose 1-3 months after the second dose. | SAGE/WHO: Novavax COVID-19 vaccine combined with any other EUL COVID-19 vaccine is considered a complete primary series. | SAGE/WHO: the need and timing of booster doses are under assessment. |
| Pfizer-BioNTech COVID-19 vaccine (EUL/WHO authorization) [14] | SAGE/WHO: Two doses (10 µg, 0.2 mL each) 8 weeks apart. | SAGE/WHO: Two doses (30 µg, 0.3 mL each) 8 weeks apart. | SAGE/WHO: Two doses (30 µg, 0.3 mL each) 4-8 weeks apart. WHO recommends an interval of 8 weeks. | SAGE/WHO: Two doses (30 µg, 0.3 mL each) 8 weeks apart. | SAGE/WHO: Extended primary series with an additional (third) 10 µg dose 1-3 months after the second dose. A booster dose has not yet been determined. | SAGE/WHO: Extended primary series with an additional (third) 30 µg dose 1-3 months after the second dose, and a booster (fourth) dose provided 4-6 months after. | SAGE/WHO: Extended primary series with an additional (third) 30 µg dose 1-3 months after the second dose, and a booster (fourth) dose provided 4-6 months after. | SAGE/WHO: Comirnaty (Pfizer-BioNTech) combined with any other EUL COVID-19 vaccine is considered a complete primary series. | SAGE/WHO: A booster dose should be given 4-6 months after the primary series*. WHO recommends Comirnaty as a heterologous booster following a primary series with another platform. |
| Sinopharm/BIBP COVID-19 vaccine (EUL/WHO authorization) [7], [15] | ANMAT/Argentina: 3 years of age and older. Two doses (0.5 mL each) 3 weeks apart. | ANMAT/Argentina: Two doses (0.5 mL each) 3 weeks apart. | SAGE/WHO: Two doses (0.5mL each) 3 weeks apart. WHO recommends an interval of 3-4 weeks. | SAGE/WHO: Two doses (0.5 mL each) 3 to 4 weeks apart. WHO recommends using the Sinopharm/BIBP COVID-19 vaccine in pregnant women only if the benefits of vaccination outweigh the potential risks. | ANMAT/Argentina: 3 years of age and older. Two doses (0.5 mL) 3 weeks apart, followed by an additional (third) dose provided 4 weeks after. | ANMAT/Argentina: 3 years of age and older. Two doses (0.5 mL) 3 weeks apart, followed by an additional (third) dose provided 4 weeks after. | SAGE/WHO: Extended primary series with an additional (third) dose of 0.5 mL 1-3 months after the second dose, followed by a booster (fourth) dose provided 3-6 months after. | SAGE/WHO: Sinopharm/BIBP COVID-19 vaccine combined with any other EUL COVID-19 vaccine is considered a complete primary series. | SAGE/WHO: A booster dose should be given 4-6 months after the primary series* using any other EUL vaccine (preferably an mRNA-based or viral vector vaccine). |
| Sinopharm/WIBP COVID-19 vaccine (Authorized) [16], [17] | Not recommended yet | Not recommended yet | NMPA/China: Two doses (0.5mL each) 3-4 weeks apart. | NMPA/China: There is insufficient data on using the Sinopharm/WIBP COVID-19 vaccine during pregnancy. | Not recommended yet | Not recommended yet | NMPA/China: Two doses (0.5mL each) 3-4 weeks apart. | NMPA/China: a heterologous booster schedule is recommended. | NMPA/China: A booster dose should be given 6 months after the primary series using a protein subunit vaccine (Anhui Zhifei vaccine) or a viral vector-based one (CanSino vaccine). |
| Sinovac COVID-19 vaccine (EUL/WHO authorization) [8], [18] | ISP/Chile: 3 years of age and older. Two doses (0.5 mL) 2-4 weeks apart. | ISP/Chile: Two doses (0.5 mL) 2-4 weeks apart. | SAGE/WHO: Two doses (0.5 mL each) 2-4 weeks apart. WHO recommends an interval of 4 weeks. | SAGE/WHO: Two doses (0.5 mL each) 2-4 weeks apart. WHO recommends using the Sinovac COVID-19 vaccine in pregnant women only if the benefits of vaccination outweigh the potential risks. | ISP/Chile: 3 years of age and older. Two doses (0.5 mL) 2-4 weeks apart and a booster (third) dose provided 2 months after. | ISP/Chile: Two doses (0.5 mL) 2-4 weeks apart and a booster (third) dose provided 2 months after. | SAGE/WHO: Extended primary series with an additional (third) dose of 0.5 mL 1-3 months after the second dose, followed by a booster (fourth) dose provided 3-6 months after. | SAGE/WHO: CoronaVac (Sinovac) combined with any other EUL COVID-19 vaccine is considered a complete primary series. | SAGE/WHO: A booster dose should be given 4-6 months after the primary series* using any other EUL vaccine (preferably an mRNA-based or viral vector vaccine). |
| Vector Institute COVID-19 vaccine (Authorized) [19] | Not recommended yet | Not recommended yet | Ministry of Health/Russian Federation: Two doses (0.5 mL) 3 weeks apart. | Ministry of Health/Russian Federation: contraindicated in pregnant women. | Not recommended yet | Not recommended yet | Ministry of Health/Russian Federation: Two doses (0.5 mL) 3 weeks apart. | There is no available data on interchangeability. | There is no available data on booster doses. |
It is suggested to use the filters to select the variables with more information
Topics |
Main advisory stakeholders |
AstraZeneca/ Oxford; SK BIO; Serum Institute of India COVID-19 vaccine
|
Bharat Biotech COVID-19 vaccine
(suspended supply)
|
CanSino COVID-19 vaccine
|
Janssen COVID-19 vaccine
|
Moderna COVID-19 vaccine
|
Novavax COVID-19 vaccine
|
Pfizer-BioNTech COVID-19 vaccine
|
Sinopharm/BIBP COVID-19 vaccine
|
Sinovac COVID-19 vaccine
|
|---|---|---|---|---|---|---|---|---|---|---|
| Efficacy against symptomatic COVID-19 in adults (95% CI) | Strategic Advisory Group of Experts on Immunization (SAGE) | 72% (63-79%) *against confirmed COVID-19 [WHO, 2022 ]. | 78% (65-86%) *against confirmed COVID-19 [WHO, 2022 ]. | 58% (40-70%) *against confirmed COVID-19 [WHO, 2022 ]. | Single dose: 67% (59-73%). Two doses: 75% (55-87%) [WHO, 2022 ]. | 93% (91-95%) *against confirmed COVID-19 [WHO, 2022 ]. | 90% (80-95%) *against confirmed COVID-19 [WHO, 2021 ]. | 91% (89-93%) **persons >16 years [WHO, 2022 ]. | 79% (66-87%) *against confirmed COVID-19 [WHO, 2022 ]. | 51% (36-62%) [WHO, 2022 ]. |
| Efficacy against symptomatic COVID-19 in adults (95% CI) | Global Advisory Committee on Vaccine Safety (GACVS) | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Efficacy against symptomatic COVID-19 in adults (95% CI) | Technical Advisory Group (TAG) | >76% [TAG, 2022 ]. | >64% [TAG, 2022 ]. | NA | >67% [TAG, 2022 ]. | >93% [TAG, 2022 ]. | >90% [TAG, 2022 ]. | >95% [TAG, 2022 ]. | >79% [TAG, 2022 ]. | >67% [TAG, 2022 ]. |
| Efficacy against symptomatic COVID-19 in adults (95% CI) | Centers for Disease Control and Prevention (CDC) | NA | NA | NA | 66% (60-71%) [CDC, 2021 ]. | 94.1% (89.3-96.8%) [CDC, 2020 ]. | 89.6% (82.4-93.8%) [Twentyman E, 2022 ] | 95.0% (90.3-97.6%) **persons >16 years [CDC, 2020 ]. | NA | NA |
| Efficacy against symptomatic COVID-19 in adults (95% CI) | Food and Drug Administration (FDA) | NA | NA | NA | 66.9% (59.0-73.4%) [FDA, 2021 ]. | 94.1% (89.3-96.8%) [FDA, 2022 ]. | NA | 95.0% (90.3-97.6%) **persons >16 years [FDA, 2022 ]. | NA | NA |
| Efficacy against symptomatic COVID-19 in adults (95% CI) | European Medicines Agency (EMA) | 74.0% (65.3-80.5%) [WHO, 2022 ]. | NA | NA | 66.9% (59.0-73.4%) [EMA, 2022 ]. | 94.1% (89.3-96.8%) [EMA, 2022 ]. | 90.4% (82.9-94.6%) [EMA, 2021 ]. | 95% **persons >16 years [EMA, 2022 ]. | NA | NA |
| Efficacy against symptomatic COVID-19 in adults (95% CI) | Regulatory Authority MHRA/UK | 66.7% (57.4-74.0%) [MHRA, 2022 ]. | NA | NA | 66.9% (59.0-73.4%) [MHRA, 2022 ]. | 94.1% (89.3-96.8%) [MHRA, 2022 ]. | NA | 95.0% (90.3-97.6%) [MHRA, 2022 ]. | NA | NA |
| Efficacy against symptomatic COVID-19 in children and adolescents (95% CI) | Strategic Advisory Group of Experts on Immunization (SAGE) | Ongoing studies. Data not yet available [WHO, 2022 ]. | Ongoing studies. Data not yet available [WHO, 2022 ]. | Ongoing studies. Data not yet available [WHO, 2022 ]. | Ongoing studies. Data not yet available [WHO, 2022 ]. | Ages 12 to 17: 93% (48-100%) [WHO, 2022 ]. | Ongoing studies. Data not yet available [WHO, 2021 ]. | Ages 5 to 11: 90.7% (67.7-98.3%). Ages 12 to 15: 100% (75-100%) [WHO, 2022 ]. | Ongoing studies. Data not yet available [WHO, 2022 ]. | Ongoing studies. Data not yet available [WHO, 2022 ]. |
| Efficacy against symptomatic COVID-19 in children and adolescents (95% CI) | Global Advisory Committee on Vaccine Safety (GACVS) | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Efficacy against symptomatic COVID-19 in children and adolescents (95% CI) | Technical Advisory Group (TAG) | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Efficacy against symptomatic COVID-19 in children and adolescents (95% CI) | Centers for Disease Control and Prevention (CDC) | NA | NA | NA | NA | 6 months to 5 years of age: 37.8% (20.9-51.1%) [CDC, 2022 ]. | NA | 6 months to 4 years of age: 80.0% (22.8-94.8%) [CDC, 2022 ]. | NA | NA |
| Efficacy against symptomatic COVID-19 in children and adolescents (95% CI) | Food and Drug Administration (FDA) | NA | NA | NA | NA | 6 to 23 months of age: 31.5% (27.7-62.0%). 2 to 5 years of age: 46.4%. (19.8-63.8%) [FDA, 2022 ]. | NA | Ages 5 to 11: 90.7% (67.7-98.3%) Ages 12 to 15: 100% (78.1-100%) [FDA, 2022 ]. | NA | NA |
| Efficacy against symptomatic COVID-19 in children and adolescents (95% CI) | European Medicines Agency (EMA) | Data not yet available [EMA, 2022 ]. | NA | NA | Data not yet available [EMA, 2022 ]. | In age groups from 6 to 17 years the efficacy is similar to that in adults [EMA, 2022 ]. | Ages 12 to 17: 79.5% (46.8-92.1%) [EMA, 2021 ]. | Ages 5 to 11: 90.7% (67.7-98.3%) Ages 12 to 15: 100% (75-100%) [EMA, 2022 ]. | NA | NA |
| Efficacy against symptomatic COVID-19 in children and adolescents (95% CI) | Regulatory Authority MHRA/UK | Data not yet available [MHRA, 2022 ]. | NA | NA | Data not yet available [MHRA, 2022 ]. | Data not yet available [MHRA, 2022 ]. | NA | Ages 5 to 11: 90.7% (67.7-98.3%) Ages 12 to 15: 100% (75.3-100.0%) [MHRA, 2022 ]. | NA | NA |
| Vaccination during pregnancy | Strategic Advisory Group of Experts on Immunization (SAGE) | Recommended if the benefits of vaccination outweigh the potential risks [WHO, 2022 ]. | Recommended if the benefits of vaccination outweigh the potential risks [WHO, 2022 ]. | Recommended if the benefits of vaccination outweigh the potential risks [WHO, 2022 ]. | Recommended if the benefits of vaccination outweigh the potential risks [WHO, 2022 ]. | Recommended [WHO, 2022 ]. | Recommended if the benefits of vaccination outweigh the potential risks [WHO, 2021 ]. | Recommended [WHO, 2022 ]. | Recommended if the benefits of vaccination outweigh the potential risks [WHO, 2022 ]. | Recommended if the benefits of vaccination outweigh the potential risks [WHO, 2022 ]. |
| Vaccination during pregnancy | Global Advisory Committee on Vaccine Safety (GACVS) | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Vaccination during pregnancy | Technical Advisory Group (TAG) | Recommended [TAG, 2022 ]. | Recommended if the benefits of vaccination outweigh the potential risks [TAG, 2022 ]. | NA | Recommended [TAG, 2022 ]. | Recommended [TAG, 2022 ]. | Recommended if the benefits of vaccination outweigh the potential risks [TAG, 2022 ]. | Recommended [TAG, 2022 ]. | Recommended [TAG, 2022 ]. | Recommended [TAG, 2022 ]. |
| Vaccination during pregnancy | Centers for Disease Control and Prevention (CDC) | NA | NA | NA | Recommended [CDC, 2022 ]. | Recommended [CDC, 2022 ]. | NA | Recommended [CDC, 2022 ]. | NA | NA |
| Vaccination during pregnancy | Food and Drug Administration (FDA) | NA | NA | NA | Available data are insufficient to inform vaccine-associated risks in pregnancy [FDA, 2021 ]. | Available data are insufficient to assess the vaccine-associated risks in pregnancy [FDA, 2022 ]. | NA | Available data are insufficient to inform vaccine-associated risks in pregnancy [FDA, 2022 ]. | NA | NA |
| Vaccination during pregnancy | European Medicines Agency (EMA) | Recommended if the benefits of vaccination outweigh the potential risks [WHO, 2022 ]. | NA | NA | Recommended if the benefits of vaccination outweigh the potential risks [EMA, 2022 ]. | Recommended [EMA, 2022 ]. | Recommended if the benefits of vaccination outweigh the potential risks [EMA, 2021 ]. | Recommended [EMA, 2022 ]. | NA | NA |
| Vaccination during pregnancy | Regulatory Authority MHRA/UK | Recommended if the benefits of vaccination outweigh the potential risks [MHRA, 2022 ]. | NA | NA | Recommended if the benefits of vaccination outweigh the potential risks [MHRA, 2022 ]. | Recommended [MHRA, 2022 ]. | NA | Recommended [MHRA, 2022 ]. | NA | NA |
| SARS-CoV-2 variants | Strategic Advisory Group of Experts on Immunization (SAGE) | Delta variant (effectiveness against hospitalization): 92% (95% CI: 75-97%) Alpha variant (effectiveness against hospitalization): 86% (95% CI: 53-96%) [WHO, 2022 ]. | Delta variant (efficacy): 65% (95% CI: 33-83%) [WHO, 2022 ]. | NA | Beta variant (South Africa, vaccine efficacy -VE-): 52.0%. Gamma variant (Brazil, VE): 68.1%. Omicron variant (South Africa, healthcare workers): effectiveness against COVID-19-related hospitalizations was 55% (95% CI: 22-74) [WHO, 2022 ]. | Delta variant (USA, effectiveness): 79.8% (95% CI: 67.4-87.5%), and 94.0% (95% CI: 92.3-95.4%) after a booster dose. Omicron variant (USA, effectiveness): 42.8% (95% CI: 33.8- 50.7%) and 67.9% (95% CI: 65.8-69.9%) after a booster dose [WHO, 2022 ]. | Alpha variant (UK, vaccine efficacy -VE-): 86% (95% CI: 71-94); and 94% (95% CI: 82-98) in USA. Beta variant (South Africa, VE): 49% (95% CI: 28-63) during circulation of Beta [WHO, 2021 ]. | Omicron variant: effectiveness is lower compared to Delta [WHO, 2022 ]. | NA | Gamma and Alpha variants (Chile, effectiveness): 65.9% (95% CI: 65-66%). Delta variant (Chile, effectiveness): 79% (95% CI: 77-81%) for a 3-dose schedule with CoronaVac (Sinovac) [WHO, 2022 ]. |
| SARS-CoV-2 variants | Global Advisory Committee on Vaccine Safety (GACVS) | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| SARS-CoV-2 variants | Technical Advisory Group (TAG) | Vaccine effectiveness against COVID-19 declines as for six months after a primary series in the context of variants of concern (including Delta and Omicron variants)[TAG, 2022 ]. | Vaccine effectiveness against COVID-19 declines as for six months after a primary series in the context of variants of concern (including Delta and Omicron variants)[TAG, 2022 ]. | NA | Vaccine effectiveness against COVID-19 declines as for six months after a primary series in the context of variants of concern (including Delta and Omicron variants)[TAG, 2022 ]. | Vaccine effectiveness against COVID-19 declines as for six months after a primary series in the context of variants of concern (including Delta and Omicron variants)[TAG, 2022 ]. | Vaccine effectiveness against COVID-19 declines as for six months after a primary series in the context of variants of concern (including Delta and Omicron variants [TAG, 2022 ]. | Vaccine effectiveness against COVID-19 declines as for six months after a primary series in the context of variants of concern (including Delta and Omicron variants)[TAG, 2022 ]. | Vaccine effectiveness against COVID-19 declines as for six months after a primary series in the context of variants of concern (including Delta and Omicron variants)[TAG, 2022 ]. | Vaccine effectiveness against COVID-19 declines as for six months after a primary series in the context of variants of concern (including Delta and Omicron variants)[TAG, 2022 ]. |
| SARS-CoV-2 variants | Centers for Disease Control and Prevention (CDC) | NA | NA | NA | NA | Omicron variant (USA): vaccine effectiveness during the BA.2/BA.2.12.2 period was lower than that during the BA.1 period [CDC, 2022 ]. | NA | Omicron variant (USA): vaccine effectiveness during the BA.2/BA.2.12.2 period was lower than that during the BA.1 period [CDC, 2022 ]. | NA | NA |
| SARS-CoV-2 variants | Food and Drug Administration (FDA) | NA | NA | NA | NA | Vaccine efficacy among ages 6 months through 5 years was evaluated during the Omicron-predominant period [FDA, 2022 ]. | NA | NA | NA | NA |
| SARS-CoV-2 variants | European Medicines Agency (EMA) | NA | NA | NA | Alpha variant (efficacy): 71.6% (95% CI: 43.2; 86.9) after the first dose, and 94.2% (95% CI: 62.9; 99.9) after a second dose [EMA, 2022 ]. | NA | The vaccine efficacy in adults was assessed while Alpha, Beta, and Gamma was circulating; in ages 12 to 17, during the Delta variant-predominant period [EMA, 2021 ]. | NA | NA | NA |
| SARS-CoV-2 variants | Regulatory Authority MHRA/UK | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Vaccine platform description | Candidate vaccine | Developers |
|---|
Last update: 2 august, 2022
Source: WHO. COVID-19 vaccine tracker and landscape
Phase vaccine not reported: COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores developed by DreamTec Research Limited